Will the 40-gene expression classifier predict responders to EGFR targeted chemotherapy for the invasive bladder cancer patients?

摘要: Bladder cancer (BC) is the second most common genitourinary malignancy and fourth in US, costs over an estimated $4 billion annually US alone. BC ranks amongst expensive treatment to date. Most patients have curable transitional cell carcinoma non-muscle invasive (NMIBC). Only approximately 30% of NMIBC progress muscle-invasive BCs (MIBC), however, about 50% these develop metastases within 2 years after cystectomy, half die 5 years. MIBC, which are notorious as heterogeneous hard-to-treat cancers, do not effectively respond adjuvant chemotherapy generally associated with a poor prognosis, causing deaths (1).